(S)-N-isopropylphenylglycinol | 459804-55-8

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: (S)-N-isopropylphenylglycinol
• 英文别名: (S)-2-(isopropylamino)-2-phenylethanol；(2S)-2-phenyl-2-(propan-2-ylamino)ethanol
• CAS: 459804-55-8
• 化学式: C₁₁H₁₇NO
• 分子量: 179.262
• InChiKey: XFSCVCVPECOHBL-LLVKDONJSA-N

物化性质

• 沸点：
  294.8±20.0 °C(Predicted)
• 密度：
  1.000±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  13
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  32.3
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  (S)-N-isopropylphenylglycinol 在 4-二甲氨基吡啶 、 三乙胺 、 对甲苯磺酰氯 作用下， 以 二氯甲烷 为溶剂， 反应 24.0h， 以67%的产率得到(2S)-1-isopropyl-2-phenylaziridine
  参考文献：
  名称：

  “在水上”：氮杂环丁烷与铁催化的氮丙啶的高效铁环加成反应

  摘要：

  在悬浮液中：氮丙啶与在Fe的存在heterocumulenes反应（NO 3）3 ⋅9ħ 2 ö在水性悬浮液中提供了访问以良好至高产率官能五元杂环。该方案具有广泛的底物范围，简单且使用无毒且廉价的催化剂。

  DOI：

  10.1002/anie.201207746
• 作为产物：
  描述：

  L-苯甘氨酸 在 sodium tetrahydroborate 、 碘 作用下， 以 四氢呋喃 、 乙醇 为溶剂， 反应 24.0h， 生成 (S)-N-isopropylphenylglycinol
  参考文献：
  名称：

  “在水上”：氮杂环丁烷与铁催化的氮丙啶的高效铁环加成反应

  摘要：

  在悬浮液中：氮丙啶与在Fe的存在heterocumulenes反应（NO 3）3 ⋅9ħ 2 ö在水性悬浮液中提供了访问以良好至高产率官能五元杂环。该方案具有广泛的底物范围，简单且使用无毒且廉价的催化剂。

  DOI：

  10.1002/anie.201207746

文献信息

• Enantioselective deprotometalation of alkyl ferrocenecarboxylates using bimetallic bases
  作者：Gandrath Dayaker、William Erb、Madani Hedidi、Floris Chevallier、Marielle Blot、Philippe C. Gros、Göran Hilmersson、Thierry Roisnel、Vincent Dorcet、Ghenia Bentabed-Ababsa、Florence Mongin

  DOI：10.1039/d1nj04526a

  日期：——

  alkyl-containing lithium zincates, 1 : 1 mixtures of lithium and zinc amides were tested. Chiral (H-exo-born-R or H-endo-born-S) or/and achiral (lithium 2,2,6,6-tetramethylpiperidide or lithium diisopropylamide) secondary amines gave good results, the best (81% yield and 44% ee in favor of the RP enantiomer) being obtained by using (endo-born-S)3ZnLi in THF at room temperature. Among other secondary amines also

  描述了使用混合锂-锌或锂-镉碱对二茂铁羧酸烷基酯 (FcCO 2 R) 进行对映选择性去金属化。以FcCO 2 Me为底物，由外-(α R )-或内-(α S ) -N- (α-苯乙基)冰片胺( H-外-本-R或H- )制备手性烷基氨基锌酸锂内生-S ) 进行了测试；最好的结果（27％产率和62％ee的赞成的[R P对映体）通过使用卜得到2（内切-born-S ) ZnLi 在四氢呋喃 (THF) 中在 -30 °C 下碘分解。由于 FcCO 2 Me 与含烷基的锌酸锂的相容性低，因此测试了氨基化锂和氨基化锌的 1:1 混合物。手性（H- exo- born- R或H- endo- born- S）或/和非手性（2,2,6,6-四甲基哌啶锂或二异丙基氨基锂）仲胺得到了很好的结果，最好的（81%的产率和44% ee 有利于R P对映异构体）是通过在室温下在 THF 中使用（内生S）3 ZnLi
• THYROID RECEPTOR LIGANDS
  申请人：Ryono Denis E.

  公开号：US20100298276A1

  公开（公告）日：2010-11-25

  Thyroid receptor ligands are provided which have the general formula I wherein: R 1 is R 2 and R 3 are the same or different and are hydrogen, halogen, alkyl of 1 to 4 carbons or cycloalkyl of 3 to 5 carbons, provided that at least one of R 2 and R 3 is other than hydrogen; R 4 is R 5 and R 6 are the same or different and are selected from hydrogen, aryl, heteroaryl, alkyl, cycloalkyl, aralkyl or heteroaralkyl. R 7 is aryl, heteroaryl, alkyl, aralkyl, or heteroaralkyl; R 8 is aryl, heteroaryl, or cycloalkyl; R 9 is R 7 or hydrogen; R 10 is hydrogen, halogen, cyano or alkyl; R 11 and R 12 are each independently selected from the group consisting of hydrogen, halogen, alkoxy, hydroxy (—OH) cyano, and alkyl; R 13 is carboxylic acid (COOH) or esters thereof, phosphonic and phosphinic acid or esters thereof, sulfonic acid, tetrazole, hydroxamic acid, thiazolidinedione, acylsulfonamide, or other carboxylic acid surrogates known in the art; R 14 and R 15 may be the same or different and are selected from hydrogen and alkyl, or R 14 and R 15 may be joined together forming a chain of 2 to 5 methylene groups [—(CH2)m-, m=2, 3, 4 or 5], thus forming 3- to 6-membered cycloalkyl rings; R 16 is hydrogen or alkyl of 1 to 4 carbons; R 17 and R 18 are the same or different and selected from hydrogen, halogen and alkyl; n is 0 or an integer from 1 to 4; X is oxygen (—O—), sulfur (—S—), sulfonyl (—SO 2 —), sulfenyl (—SO—) selenium (—Se—), carbonyl (—CO—), amino (—NH—) or methylene (—CH2-); wherein the substituents are as described herein. In addition, a method is provided for preventing, inhibiting or treating diseases or disorders associated with metabolism dysfunction or which are dependent upon the expression of a T 3 regulated gene, wherein a compound as described above is administered in a therapeutically effective amount.

  提供了甲状腺受体配体，其具有一般公式I，其中：R1为R2和R3，R2和R3相同或不同，为氢、卤素、1至4个碳原子的烷基或3至5个碳原子的环烷基，但至少其中一个为非氢；R4为R5和R6，R5和R6相同或不同，选择自氢、芳基、杂环芳基、烷基、环烷基、芳基烷基或杂环芳基；R7为芳基、杂环芳基、烷基、芳基烷基或杂环芳基；R8为芳基、杂环芳基或环烷基；R9为R7或氢；R10为氢、卤素、氰基或烷基；R11和R12各自独立选择自氢、卤素、烷氧基、羟基（—OH）、氰基和烷基；R13为羧酸（COOH）或其酯、膦酸和膦酸酯、磺酸、四唑、羟胺酸、噻唑二酮、酰基磺胺或艺术中已知的其他羧酸替代物；R14和R15可相同或不同，选择自氢和烷基，或R14和R15可结合形成2至5个亚甲基组成的链[—(CH2)m-，m=2、3、4或5]，从而形成3至6成员的环烷基环；R16为氢或1至4个碳原子的烷基；R17和R18相同或不同，选择自氢、卤素和烷基；n为0或1至4的整数；X为氧（—O—）、硫（—S—）、砜基（—SO2—）、砜基（—SO—）、硒（—Se—）、羰基（—CO—）、氨基（—NH—）或亚甲基（—CH2-）；其中取代基如上述所述。此外，提供了一种方法，用于预防、抑制或治疗与代谢功能障碍或依赖于T3调节基因表达的疾病或障碍，其中上述化合物以治疗有效剂量给予。
• PHENYLPYRAZOLE DERIVATIVES AS POTENT ROCK1 AND ROCK2 INHIBITORS
  申请人：Bristol-Myers Squibb Company

  公开号：US20140243338A1

  公开（公告）日：2014-08-28

  The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective ROCK inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating cardiovascular, smooth muscle, oncologic, neuropathologic, autoimmune, fibrotic, and/or inflammatory disorders using the same.

  本发明提供了式(I)的化合物：或其立体异构体、互变异构体或药学上可接受的盐，其中所有变量如本文所定义。这些化合物是选择性ROCK抑制剂。本发明还涉及包含这些化合物的药物组合物以及使用这些药物组合物治疗心血管、平滑肌、肿瘤学、神经病理学、自身免疫、纤维化和/或炎症性疾病的方法。
• Asymmetric addition of n-butyllithium to aldehydes: new insights into the reactivity and enantioselectivity of the chiral amino ether accelerated reaction
  作者：Johan Granander、Richard Sott、Göran Hilmersson

  DOI：10.1016/s0040-4020(02)00378-2

  日期：2002.6

  Enantioselective butylation of benzaldehyde with n-butyllithium was mediated by a series of chiral lithium amide analogues to give 1-phenylpentanol in good to moderate enantioselectivities. In order to achieve high enantiomeric excess in the reaction, the lithium amide must have a substituent larger than methyl on both the carbon at the stereogenic center and the nitrogen. Computational studies, using

  通过一系列手性锂酰胺类似物介导苯甲醛与正丁基锂的对映选择性丁基化反应，得到1-苯戊醇，具有良好至中等的对映选择性。为了在反应中实现高的对映体过量，在立构中心的碳和氮上，酰胺化锂必须具有大于甲基的取代基。使用半经验（PM3）和密度泛函（B3LYP）方法进行的计算研究表明，手性锂酰胺加速异丁醛丁基化的过渡态的稳定性与实验一致。
• URACIL DERIVATIVE AND USE THEREOF FOR MEDICAL PURPOSES
  申请人：Shiro Tomoya

  公开号：US20140179670A1

  公开（公告）日：2014-06-26

  The present invention provides: an uracil derivative represented by general formula (I) or a physiologically acceptable salt thereof (in the formula, R 1 represents a hydrogen atom, a C 1-10 alkyl group, a C 2-6 alkene group or a 3- to 6-membered saturated or 4- to 6-membered unsaturated aliphatic ring group which may contain 1 to 2 hetero atoms independently selected from the group consisting of N, O and S; R 2 represents a hydrogen atom, a halogen atom, a cyano group, —NR c R d , —N═CHN(CH 3 ) 2 , or an C 1-3 alkyl group; Ar 1 and Ar 2 independently represent a 5- to 6-membered aromatic ring group which may contain 1 to 3 hetero atoms independently selected from the group consisting of N, O and S; and L represents a 6-membered aromatic ring group which may contain 1 to 4 nitrogen atoms, a pyrazole group, a triazole group, or an imidazole group); and a therapeutic agent or prophylactic agent for various inflammatory diseases associated with elastase, comprises the compound or the like as an active ingredient.

  本发明提供：一种尿嘧啶衍生物，其由通式（I）表示，或其生理上可接受的盐（在该式中，R1代表氢原子，C1-10烷基，C2-6烯基或3-至6-成员饱和或4-至6-成员不饱和的脂肪环基，该环基可以独立地选择来自N，O和S的1到2个杂原子；R2代表氢原子，卤素原子，氰基，—NRcRd，—N═CHN(CH3)2或C1-3烷基；Ar1和Ar2独立地表示5-至6-成员芳香环基，该环基可以独立地选择来自N，O和S的1到3个杂原子；L表示6-成员芳香环基，该环基可以包含1到4个氮原子，吡唑基，三唑基或咪唑基）；以及用作与弹性酶相关的各种炎症性疾病的治疗剂或预防剂，包括该化合物或类似物作为活性成分。